John P. Schmid
CIK 1478916 · Chief Financial Officer · last filed 2026-08-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ANAB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6005 HIDDEN VALLEY ROAD, SUITE 110
CARLSBAD, CA 92011
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) Delisted | Director | 6,000 | $16.31 | $97.9K | $96.0K | 1 | 2026-08-10 |
| ANAB | Director | 37,652 | $49.84 | $1.88M | -$1.16M | 18 | 2026-06-17 |
| TRAX | Director | 37,652 | $45.67 | $1.72M | $0 | 4 | 2026-06-17 |
| DSGN | Director | 57,639 | $10.49 | $604.6K | $99.7K | 7 | 2026-06-11 |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | 30,000 | $9.90 | $297.0K | $0 | 1 | 2025-08-11 | |
| Poseida Therapeutics, Inc. (PSTX) Delisted | Director | 0 | $9.50 | $0 | $0 | 7 | 2025-01-08 |
| XERS | Director | 138,359 | $10.46 | $1.45M | $50.1K | 12 | 2024-08-13 |
| Neos Therapeutics, Inc. (NEOS) Delisted | Director | 0 | $1.15 | $0 | $0 | 6 | 2021-03-19 |
| Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Chief Financial Officer | 0 | — | — | $0 | 2 | 2015-05-06 |
| Trius Therapeutics Inc (TSRX) Delisted | Chief Financial Officer | 107,639 | — | — | -$85.0K | 23 | 2013-03-11 |
Recent Filings · Page 7 of 9
84 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-09-13 | — | Disp (D) | −107,639 | $0 | |
| 2013-03-11 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-25 | Trius Therapeutics Inc (TSRX) Delisted | Sell (S) | −1,800 | -$10.8K | EDGAR |
| 2012-03-28 | Trius Therapeutics Inc (TSRX) Delisted | Exer (M) | +5,000 | $6.5K | EDGAR |
| 2012-03-12 | Trius Therapeutics Inc (TSRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-03-02 | Trius Therapeutics Inc (TSRX) Delisted | Sell (S) | −500 | -$2.5K | EDGAR |
| 2012-02-06 | Trius Therapeutics Inc (TSRX) Delisted | Sell (S) | −500 | -$2.8K | EDGAR |
| 2012-01-04 | Trius Therapeutics Inc (TSRX) Delisted | Sell (S) | −700 | -$5.1K | EDGAR |
| 2011-12-02 | Trius Therapeutics Inc (TSRX) Delisted | Sell (S) | −700 | -$5.2K | EDGAR |
| 2011-11-08 | Trius Therapeutics Inc (TSRX) Delisted | Sell (S) | −100 | -$700 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.